YU90203A - Upotreba adenozina i analoga za izradu lekova za tretman sindroma rezistentnosti na insulin i dijabetesa - Google Patents

Upotreba adenozina i analoga za izradu lekova za tretman sindroma rezistentnosti na insulin i dijabetesa

Info

Publication number
YU90203A
YU90203A YU90203A YUP90203A YU90203A YU 90203 A YU90203 A YU 90203A YU 90203 A YU90203 A YU 90203A YU P90203 A YUP90203 A YU P90203A YU 90203 A YU90203 A YU 90203A
Authority
YU
Yugoslavia
Prior art keywords
alkyl
hydrogen
diabetes
treatment
insulin resistance
Prior art date
Application number
YU90203A
Other languages
English (en)
Inventor
Andreas Herling
Gerhard Jahne
Michael R. Myers
Martin P. Maguire
Alfred P. Spade
William R. Ewing
Henry W. Pauls
Yong Mi Choi-Sledeski
Original Assignee
Aventis Pharma Deutschland Gmbh.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Deutschland Gmbh. filed Critical Aventis Pharma Deutschland Gmbh.
Publication of YU90203A publication Critical patent/YU90203A/sh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16Purine radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

Pronalazak se odnosi na upotrebu jedinjenja adenozina koja su opisana formulom (I) i neke njihove derivate za izradu leka za tretman sindroma rezistencije na insulin i dijabetesa. U formuli (I), K je N, NO ili CH; Q je CH2 ili O; R6 je vodonik, alkil, alil, 2-metalil, 2-butenil ili cikloalkil grupa; X je (a) ili (b); E je O ili S; Y je, na primer, vodonik, alkil, aralkil, aril grupa; n i p su nezavisno 0, 1, 2 ili 3 pod uslovom da je n+p najmanje 1; T je, na primer, vodonik, alkil, acil, tioacil, halo, karboksilna grupa; R1, R2 i R3 su nezavisno H, alkil ili cikloalkil grupa; A je vodonik, alkil, hidroksialkil, alkoksialkil ili OR', B je vodonik, alkil, hidroksialkil, alkoksialkil ili OR'', R' i R'' su, na primer, nezavisno vodonik, alkil, aralkil ili karbamoil grupa.[The invention relates to the use of adenosine compounds described by formula (I) and certain derivatives thereof for producing a medicine for the treatment of the insulin resistance syndrome and diabetes. In formula (I), K is N, NO, or CH; Q is CH2 or O; R6 is hydrogen, alkyl, allyl, 2-methallyl, 2-butenyl, or cycloalkyl; X is (a) or (b); E is O or S; Y is e.g. hydrogen, alkyl, aralkyl, aryl; n and p are independently 0, 1, 2 or 3 provided that n + p is at least 1; T is e.g. hydrogen, alkyl, acyl, thioacyl, halo, carboxyl; R1, R2 and R3 are independently H, alkyl, or cycloalkyl; A is hydrogen, alkyl, hydroxyalkyl, alkoxyalkyl, or OR'; B is hydrogen, alkyl, hydroxyalkyl, alkoxyalkyl, or OR''; R' and R'' are e.g independently hydrogen, alkyl, aralkyl or carbamoyl.
YU90203A 2001-05-14 2002-05-14 Upotreba adenozina i analoga za izradu lekova za tretman sindroma rezistentnosti na insulin i dijabetesa YU90203A (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01111651A EP1258247A1 (en) 2001-05-14 2001-05-14 Adenosine analogues for the treatment of insulin resistance syndrome and diabetes

Publications (1)

Publication Number Publication Date
YU90203A true YU90203A (sh) 2006-08-17

Family

ID=8177414

Family Applications (1)

Application Number Title Priority Date Filing Date
YU90203A YU90203A (sh) 2001-05-14 2002-05-14 Upotreba adenozina i analoga za izradu lekova za tretman sindroma rezistentnosti na insulin i dijabetesa

Country Status (23)

Country Link
US (1) US20030176390A1 (sh)
EP (2) EP1258247A1 (sh)
JP (1) JP2004533448A (sh)
KR (1) KR20040002962A (sh)
CN (1) CN1518450A (sh)
BG (1) BG108356A (sh)
BR (1) BR0209650A (sh)
CA (1) CA2447408A1 (sh)
CO (1) CO5540288A2 (sh)
CZ (1) CZ20033079A3 (sh)
EA (1) EA007253B1 (sh)
EE (1) EE200300551A (sh)
HR (1) HRP20030928A2 (sh)
HU (1) HUP0400464A3 (sh)
IL (1) IL158794A0 (sh)
MX (1) MXPA03010336A (sh)
NO (1) NO20035056D0 (sh)
NZ (1) NZ529390A (sh)
PL (1) PL364573A1 (sh)
SK (1) SK14052003A3 (sh)
WO (1) WO2002092093A1 (sh)
YU (1) YU90203A (sh)
ZA (1) ZA200308777B (sh)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT200500281A (es) * 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0500785D0 (en) * 2005-01-14 2005-02-23 Novartis Ag Organic compounds
GB0607944D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607950D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
KR20080110925A (ko) 2006-04-21 2008-12-19 노파르티스 아게 아데노신 a2a 수용체 효능제로서 사용하기 위한 퓨린 유도체
GB0607948D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607953D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
EP1889846A1 (en) 2006-07-13 2008-02-20 Novartis AG Purine derivatives as A2a agonists
EP1903044A1 (en) * 2006-09-14 2008-03-26 Novartis AG Adenosine Derivatives as A2A Receptor Agonists
BRPI0718792A2 (pt) * 2006-11-10 2013-12-03 Novartis Ag Compostos orgânicos
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2009131196A1 (ja) * 2008-04-24 2009-10-29 武田薬品工業株式会社 置換ピロリジン誘導体およびその用途
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8729994D0 (en) * 1987-12-23 1988-02-03 Glaxo Group Ltd Chemical compounds
US5055569A (en) * 1989-10-19 1991-10-08 G. D. Searle & Co. N-(6)-substituted adenosine compounds
HUT61567A (en) * 1990-12-07 1993-01-28 Sandoz Ag Process for producing new pharmaceutical compositions comprising 2'-o-alkyladenosine derivatives and for producing 6-cyclohexyl-2'-o-methyladenosinehydrate
US6376472B1 (en) * 1996-07-08 2002-04-23 Aventis Pharmaceuticals, Inc. Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties
UA51716C2 (uk) * 1996-07-08 2002-12-16 Авентіс Фармасьютікалз Продактс Інк. Сполуки, що мають гіпотензивну, кардіопротекторну, анти-ішемічну та антиліполітичну властивості, фармацевтична композиція та способи лікування
GB9723590D0 (en) * 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds
US6258793B1 (en) * 1999-12-03 2001-07-10 Cv Therapeutics, Inc. N6 heterocyclic 5′ modified adenosine derivatives

Also Published As

Publication number Publication date
ZA200308777B (en) 2006-04-26
IL158794A0 (en) 2004-05-12
EP1404338A1 (en) 2004-04-07
US20030176390A1 (en) 2003-09-18
BR0209650A (pt) 2004-07-13
KR20040002962A (ko) 2004-01-07
JP2004533448A (ja) 2004-11-04
CO5540288A2 (es) 2005-07-29
HRP20030928A2 (en) 2005-10-31
CZ20033079A3 (cs) 2004-08-18
WO2002092093A1 (en) 2002-11-21
CA2447408A1 (en) 2002-11-21
EA200301231A1 (ru) 2004-04-29
CN1518450A (zh) 2004-08-04
BG108356A (bg) 2004-12-30
EA007253B1 (ru) 2006-08-25
NZ529390A (en) 2006-06-30
HUP0400464A3 (en) 2007-03-28
HUP0400464A2 (hu) 2004-07-28
EP1258247A1 (en) 2002-11-20
NO20035056D0 (no) 2003-11-13
MXPA03010336A (es) 2004-03-16
SK14052003A3 (sk) 2004-07-07
PL364573A1 (en) 2004-12-13
EE200300551A (et) 2004-02-16

Similar Documents

Publication Publication Date Title
MXPA03010336A (es) Analogos de adenosina para el tratamiento del sindrome de resistencia a la insulina y diabetes.
GB0206860D0 (en) Compounds
ATE120644T1 (de) Verwendung von 1,3-oxathiolanalogen von nukleosiden zur herstellung eines arzneimittels zur behandlung von hepatitis-b.
DE69531502D1 (de) Monoamid, diamid, thiol enthaltende metall-chelatierende verbindungen
ZA9290B (en) Phenylimidazolidines,process for their preparation,their use as medicaments and pharmaceutical compositions containing them
HU9301585D0 (en) Methods for producing phenyl-imidazolydine derivatives as well as medical preparatives containing said compounds
DE60019904D1 (de) Verwendung von sulfamat derivaten zur behandlung von impulsiven störungen
HUP0004531A2 (hu) VLA-4 által mediált leukocita adhéziót gátló 4-aminofenilalanin-vegyületek, ezeket tartalmazó gyógyászati készítmények, valamint alkalmazásuk
NO20051209L (no) Pyrazolderivater, medisinske sammensetninger inneholdende slike, medisinsk anvendelse derav samt intermediater for samme
HUP0202655A2 (hu) N-[(amino-imino-metil)- és N-[(amino-metil)-fenil]-propil-amid származékok
DE69416306D1 (de) Sphingoglycolipid und verwendung davon
YU77701A (sh) 3-α-HIDROKSI-3Гџ-METOKSIMETIL-21-HETEROCIKLIČNO SUPSTITUISANI STEROIDI SA ANESTETIČKIM DEJSTVOM
DE60330407D1 (de) Synthese von Epothilonen, Zwischenprodukte davon, Analoga und ihre Verwendung
DK0756595T3 (da) Substituerede 1,3-oxathiolaner med antivirale egenskaber
GEP20084284B (en) Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
MX9700928A (es) Derivado de triazian y medicina que lo contiene.
ATE37869T1 (de) Benzoylharnstoffderivate und diese verbindungen enthaltende pestizide kompositionen.
DK0646578T3 (da) Phenylcarboxamidisoxazoler og deres salte, fremgangsmåde til deres fremstilling, deres anvendelse som lægemidler og farmace
MXPA05014068A (es) Dicetopiperazinas sustituidas y su uso como antagonistas de oxitocina.
TW200420567A (en) Quinazoline derivatives
ATE28862T1 (de) Aktive kompositionen gegen motten, weisse fliegen und holzwuermer, pharmazeutische kompositionen und benzoylharnstoffderivaten.
TW259785B (en) Chemical compounds
GR3021770T3 (en) Substituted piperazines, their process of preparation and the pharmaceutical compositions containing them.
RU2003130062A (ru) Бициклические производные гуанидина и их терапевтическое использование
HUP0000934A1 (hu) 4-{2-[N-(3-Fenoxi-2-hidroxi)-propil-amino]-etil}-anilid-származékok és az ezeket tartalmazó gyógyászati készítmények